IMTX लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 108926 min ago

@ $11.29

जारी किया गया: 14 Feb 2024 @ 02:03

वापसी: -11.34%

पिछला सिग्नल: Feb 13 - 20:00

पिछला सिग्नल: खरीदें

वापसी: 2.98 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 01:30):

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States...

Stats
आज की मात्रा	290 462
औसत मात्रा	430 561
बाजार मूल्य	1.03B
EPS	$0 ( 2024-03-19 )
अगली कमाई की तारीख	( $-0.740 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.82
ATR14	$0.00800 (0.08%)

मात्रा सहसंबंध

लंबा: 0.01 (neutral)

छोटा: 0.65 (weak)

Signal:(56.361) Neutral

Immatics N.V. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
RMRM	0.966
RXT	0.929
SWAV	0.925
UCBI	0.922
NFE	0.918
CCRN	0.917
NVTSW	0.916
GBCI	0.915
FIBK	0.914
THTX	0.914

10 सबसे अधिक नकारात्मक सहसंबंध
MLCO	-0.927
EZGO	-0.926
RXDX	-0.925
FWONK	-0.922
BRAC	-0.92
LUNA	-0.918
HWCC	-0.917
BKNG	-0.917
MLVF	-0.916
MOMO	-0.915

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Immatics N.V. सहसंबंध - मुद्रा/वस्त्र

0.45
( neutral )

0.43
( neutral )

0.00
( neutral )

0.44
( neutral )

0.56
( weak )

-0.20
( neutral )

Immatics N.V. वित्तीय

Annual	2023
राजस्व:	$54.00M
सकल लाभ:	$-64.67M (-119.76 %)
EPS:	$-1.200

FY	2023
राजस्व:	$54.00M
सकल लाभ:	$-64.67M (-119.76 %)
EPS:	$-1.200

FY	2022
राजस्व:	$172.83M
सकल लाभ:	$66.05M (38.22 %)
EPS:	$0.550

Financial Reports:

No articles found.

Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.